The Early/Expanded Access Committee has been continuing to work on getting additional sites open for men with advanced prostate cancer to get access to the yet unapproved drug Radium-233 Chloride (Alapharadin). Due to the hard work of this committee there are now sites in seven different states. In order to qualify for this treatment you [...]
I have written much about the need to begin studies of both timing and combining of the many new treatments we have recently developed for the treatment of advanced prostate cancer. With the FDA approval of Provenge, Zytiga, Jevtana, Xtandi and hopefully in the near future Radium-223 Dichloride (Alpharadin) we have many new treatment options [...]
We all know that LHRH agonists are used for androgen deprivation therapy (ADT) cause a tremendous number of side effects, but it is not uncommon for our doctors to never discuss these potential side effects with us prior to starting therapy. Additionally, doctors neglect to offer alternative therapies that might accomplish the same results (like [...]
We are again looking at a potentially new block buster drug to treat men with advanced prostate cancer whose cancer has become castrate resistant. This potential drug seems to have clinical activity in both soft tissue and bone mets. This investigational drug is called Cabozantinib (XL184). It is a tyrosine kinase inhibitor with activity against [...]
A very common side effect of any cancer treatment including chemotherapy (docetaxil for men with advanced prostate cancer) and radiation is nausea. In addition to feelings of nausea many men also experience a feeling of fullness, a change in the way foods taste and strong heartburn. If you have this experience let your doctor know [...]